目錄:MedChemExpress LLC>>生化試劑>> Beraprost sodium | MCE
參考價(jià) | ¥ 3000 |
參考價(jià) | ¥ 3000 |
更新時(shí)間:2023-06-15 18:59:55瀏覽次數(shù):139評(píng)價(jià)
聯(lián)系我們時(shí)請(qǐng)說明是化工儀器網(wǎng)上看到的信息,謝謝!
CAS | 496807-11-5 | 純度 | 99.88% |
---|---|---|---|
分子量 | 420.47 | 分子式 | C??H??NaO? |
供貨周期 | 現(xiàn)貨 | 規(guī)格 | 5 mg |
貨號(hào) | HY-13569A | 應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。
CAS No. : 496807-11-5
產(chǎn)品活性:Beraprost sodium, a prostacyclin analog, is a stable and orally active proagent of PGI2. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation.
研究領(lǐng)域:GPCR/G Protein
作用靶點(diǎn):Prostaglandin Receptor
In Vitro: Beraprost sodium (0.1, 1.0, and 10.0?μM; 24 hours) treatment leads to a significant increase in the number of tube formation, BPS plays an important role on angiogenic activity. Beraprost sodium (0.1, 1.0, and 10.0?μM; 24 hours) treatment let VE-cadherin at regions of cell–cell contact becomes more abundant and the morphology of endothelial cells tends to be normal compared with those cultured under hypoxia conditions.
In Vivo: Beraprost sodium (oral adminstration; 0.6?mg/kg; once daily; 3 or 7 days) can mitigate the development of renal interstitial fibrosis, decrease renal oxidative stress through its potential vasodilation effect, and further prevent renal interstitial fibrosis.
相關(guān)產(chǎn)品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | GPCR/G Protein Compound Library | Immunology/Inflammation Compound Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Oxygen Sensing Compound Library | Anti-Cardiovascular Disease Compound Library | NMPA-Approved Drug Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Angiogenesis-Related Compound Library | Rare Diseases Drug Library | Children’s Drug Library | Coagulation and Anti-coagulation Compound Library | Off-patent Drug Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | CAY10580 | EP3 antagonist 3 | Dinoprost-d4 | TCS 2510 | Vidupiprant | EP2 receptor antagonist-1 | SC 51089 | SC-51322 | Misoprostol acid | Treprostinil sodium | Aganepag isopropyl | Prostaglandin E2 | Taprostene | Cicaprost | Fevipiprant | Carboprost | TG6-10-1 | Latanoprost acid | Carbacyclin | KW-8232 free base | Nocloprost | Cloprostenol isopropyl ester | ICI 192605 | HHS-0701 | Bimatoprost-d5 | AS604872 | KF 13218
熱門產(chǎn)品線:重組蛋白 | 化合物庫 | 天然產(chǎn)物 | 熒光染料 | PROTAC | 同位素標(biāo)記物 | 寡核苷酸 | 抗體 | 點(diǎn)擊化學(xué)
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種*僅有化合物庫,我們致力于為*科研客戶提供前沿的高品質(zhì)小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動(dòng)劑涉及各熱門信號(hào)通路及疾病領(lǐng);
• 產(chǎn)品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產(chǎn)品,廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項(xiàng)目;
• 提供虛擬篩選,離子通道篩選,代謝組學(xué)分析檢測分析,藥物篩選等專業(yè)技術(shù)服務(wù);
• 設(shè)有專業(yè)的實(shí)驗(yàn)中心和嚴(yán)格的質(zhì)控、驗(yàn)證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項(xiàng)質(zhì)檢報(bào)告,確保產(chǎn)品的高純度、高品質(zhì);
• 產(chǎn)品的生物活性多經(jīng)各國客戶實(shí)驗(yàn)驗(yàn)證;
• Nature, Cell, Science 等多種頂級(jí)期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業(yè)團(tuán)隊(duì)跟蹤最新的制藥及生命科學(xué)研究進(jìn)展,為您提供*新的活性化合物;
• 與世界各大制藥公司及著名科研機(jī)構(gòu)建立了長期的合作。
(空格分隔,最多3個(gè),單個(gè)標(biāo)簽最多10個(gè)字符)